Innovation Pharmaceuticals Requesting European Medicines Agency (EMA) Input for International Phase 3 Brilacidin Oral Mucositis Program

NEXT STORY
Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
PREV STORY
ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

mHealth Apps Market Size 2021 | Is Projected to Reach USD 57.57 billion and Exhibit a CAGR of 21.1% by 2026

author_avatar
NASDAQ Market News

Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults

First FDA-Approved Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease ...

author_avatar
NASDAQ Market News

Athenex Announces $100 Million Private Placement

author_avatar
NASDAQ Market News